Please try another search
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing of vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, it offers specialized virology and immunology laboratory, which offers a suite of services to support pre-clinical and clinical respiratory drug; and vaccine discovery and development. Further, the company provides preclinical and early clinical research services; sales and marketing services; data management; and statistics services, as well as drug development consultancy and services. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Elaine Sullivan | 60 | 2020 | Independent Non-Executive Director |
John Oxford | - | 2020 | Chair of Advisory Board |
Michael Meade | 60 | 2020 | Independent Non-Executive Director |
Brendan Buckley | 71 | - | Member of Advisory Board & Non-Executive Director |
Martin John Gouldstone | 55 | 2022 | Independent Non-Executive Director |
Yamin Mohammed Khan | 52 | 2021 | CEO & Director |
Stephen Pinkerton | - | 2022 | CFO & Executive Director |
Cathal Martin Friel | 58 | 2020 | Chairman of the Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review